Holen Sie sich die Stockscreener-App
0.98
6.67%
-0.07
Schlusskurs vom Vortag:
$1.05
Offen:
$1.03
24-Stunden-Volumen:
321.47K
Relative Volume:
0.52
Marktkapitalisierung:
$31.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.37M
KGV:
-0.9171
EPS:
-1.0686
Netto-Cashflow:
$-34.94M
1W Leistung:
+11.59%
1M Leistung:
-19.01%
6M Leistung:
-76.78%
1J Leistung:
-68.39%
1-Tages-Spanne:
$0.9798
$1.05
1-Wochen-Bereich:
$0.8301
$1.15
52-Wochen-Spanne:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Vergleichen Sie SKYE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
3.65 | 4.83B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.66 | 416.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.75 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.57 | 357.42M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
47.51 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-08-15 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
What margin trends mean for Skye Bioscience Inc. stockJuly 2025 Closing Moves & Stepwise Swing Trade Plans - ulpravda.ru
SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
SKYE FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE - GlobeNewswire Inc.
Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Skye Bioscience, Inc. ... - Bluefield Daily Telegraph
What Investors Can Learn from the Skye Bioscience Securities Fraud Allegations: A Risk Assessment Guide - TipRanks
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - FinancialContent
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your RightsSKYE - Sahm
Is Skye Bioscience Inc. (09R) stock a safe buy pre earnings2025 Winners & Losers & AI Powered Trade Plan Recommendations - ulpravda.ru
Is Skye Bioscience Inc. stock a safe haven assetQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - ulpravda.ru
Securities Lawsuit Alert: Skye Bioscience, Inc. (SKYE)Contact Levi & Korsinsky Before January 16, 2026 - ACCESS Newswire
Levi & Korsinsky Notifies Skye Bioscience, Inc. (SKYE) InvestorsLead Plaintiff Deadline on January 16, 2026 - ACCESS Newswire
Class Action Filed Against Skye Bioscience, Inc. (SKYE) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire
Why hedge funds are buying Skye Bioscience Inc. stock2025 Investor Takeaways & AI Forecast Swing Trade Picks - ulpravda.ru
Bronstein, Gewirtz & Grossman LLC Urges Skye Bioscience, - GlobeNewswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pend - GuruFocus
Treasury Yields: Is Skye Bioscience Inc. (09R) stock worth holding before Fed meetingPortfolio Gains Summary & Daily Stock Trend Watchlist - ulpravda.ru
Lawsuit Alert: Investors who lost money with shares of Skye - openPR.com
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Your Wyoming Link
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Burned by Skye Bioscience, Inc.? Contact Levi & Korsinsky to SueWallSt And Fight Back - ACCESS Newswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Se - GuruFocus
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - Your Wyoming Link
Levi & Korsinsky Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SKYE - GlobeNewswire
ROSEN, A TOP-RANKED LAW FIRM, Encourages Skye Bioscience, - GlobeNewswire
SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
SKYE LAWSUIT ALERT: Levi & Korsinsky Notifies Skye Bioscience, Inc. InvestorsLead Plaintiff Deadline January 16, 2026 - ACCESS Newswire
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm - PR Newswire
Lost Money on Skye Bioscience, Inc. (SKYE)? Contact Levi & Korsinsky Before January 16, 2026 to Join Class Action - ACCESS Newswire
HALO, Skye Bioscience team up on obesity drug development - Longevity.Technology
Lost Money on Skye Bioscience, Inc. (SKYE)? Contact Levi & Korsinsky to Join Class Action Before January 16, 2026 - ACCESS Newswire
Skye Bioscience, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your RightsSKYE - Finviz
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors - GlobeNewswire
Fibonacci Retracement Aligns with Support in Rudra Ecovation LimitedEx-Dividend Date Alerts & Free Long-Term Investment Planning - earlytimes.in
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Investors in Skye Bioscience, Inc. (SKYE): Protect Your RightsContact Levi & Korsinsky Before January 16, 2026 - ACCESS Newswire
Shareholders SueWallSt in New Class Action Against Skye Bioscience, Inc.Act Now - ACCESS Newswire
Shareholders of Skye Bioscience, Inc. (SKYE): Protect Your Rights Before January 16, 2026Contact Levi & Korsinsky - ACCESS Newswire
Citizens reiterates Market Outperform rating on Skye Bioscience stock By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of Skye Bioscience, Inc - GuruFocus
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - MarketScreener
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
The Gross Law Firm Notifies Shareholders of Skye Bioscience, Inc.(SKYE) of a Class Action Lawsuit and an Upcoming Deadline - Barchart.com
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Skye Bioscience rises as it partners with Halozyme on obesity drug - TradingView — Track All Markets
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
SKYE ALERT: Securities Fraud Class Action Launched Against Skye Bioscience, Inc.January 16, 2026 Deadline - ACCESS Newswire
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Skye Bioscience Inc-Aktie (SKYE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):